DCVC Announcements
First Investment: 2021
Shennon has built an ultra-high-throughput profiling engine that allows it to analyze millions of immune cells on the single-cell level, searching for rare receptors and other targets that will help the company create more effective immunotherapies for solid tumors.
News & Insights
Explore Companies
Syntax Bio
Programming stem cells to differentiate into desired cell types, faster
Fable Therapeutics
Using state-of-the-art machine learning models to create custom-build protein drugs
Nilo Therapeutics
Mapping the brain-body axis to achieve proper immune balance
Avicenna Biosciences
Using AI to speed through the last mile of drug discovery